CN100482236C - 用于治疗乙型肝炎的β-L-2’-脱氧-核苷 - Google Patents
用于治疗乙型肝炎的β-L-2’-脱氧-核苷 Download PDFInfo
- Publication number
- CN100482236C CN100482236C CNB021265739A CN02126573A CN100482236C CN 100482236 C CN100482236 C CN 100482236C CN B021265739 A CNB021265739 A CN B021265739A CN 02126573 A CN02126573 A CN 02126573A CN 100482236 C CN100482236 C CN 100482236C
- Authority
- CN
- China
- Prior art keywords
- purposes
- pharmaceutically acceptable
- medicament forms
- chemical compound
- acceptable medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
抑制剂 | WHV DNAIC<sub>50</sub> | DNA αK<sub>i</sub>b(μM) | DNA βK<sub>i</sub>b(μM) | DNA γK<sub>i</sub>b(μM) |
β-L-dT-TP | 0.34 | >100 | >100 | >100 |
β-L-dA-TP | 2.3 | >100 | >100 | >100 |
β-L-dC-TP | 2.0 | >100 | >100 | >100 |
β-L-dU-TP | 8 | >100 | >100 | >100 |
化合物 | HBV病毒颗粒aEC<sub>50</sub>(μM) | HBV RibEC<sub>50</sub>(μM) | 细胞毒性1C<sub>50</sub>(μM) | 选择性指数1C<sub>50</sub>/EC<sub>50</sub> |
β-L-dT | 0.05 | 0.05 | >200 | >4000 |
β-L-dC | 0.05 | 0.05 | >200 | >4000 |
β-L-dA | 0.05 | 0.05 | >200 | >2000 |
β-L-dI | 1.0 | 1.0 | >200 | >200 |
β-L-dU | 5.0 | 5.0 | >200 | >40 |
组合物 | 比例 | EC<sub>50</sub> |
L-dC+L-dT | 1:3 | 0.023 |
L-dC+L-dT | 1:1 | 0.053 |
L-dC+L-dT | 3:1 | 0.039 |
L-dC+L-dA | 1:30 | 0.022 |
L-dC+L-dA | 1:10 | 0.041 |
L-dC+L-dA | 1:3 | 0.075 |
L-dT+L-dA | 1:30 | 0.054 |
L-dT+L-dA | 1:10 | 0.077 |
L-dT+L-dA | 1:3 | 0.035 |
aβ-L-2′-脱氧腺苷(μM) | bβ-L-2′-脱氧胞苷(μM) | 抑制率% | cC.I. |
0.5 | 90 | ||
0.05 | 24 | ||
0.005 | 1 | ||
0.5 | 95 | ||
0.05 | 40 | ||
0.005 | 10 | ||
0.05 | 0.05 | 80 | 0.34 |
0.05 | 0.005 | 56 | 0.20 |
0.05 | 0.0005 | 50 | 0.56 |
0.005 | 0.05 | 72 | 0.35 |
0.005 | 0.005 | 54 | 0.35 |
0.005 | 0.0005 | 30 | 0.16 |
0.0005 | 0.05 | 50 | 0.83 |
0.0005 | 0.005 | 15 | 0.28 |
0.0005 | 0.0005 | 0 | N.A. |
化合物 | CFU-GM(μM) | BFU-E(μM) |
β-L-dA | >10 | >10 |
β-L-dC | >10 | >10 |
β-L-dT | >10 | >10 |
β-L-dU | >10 | >10 |
拉米夫定 | >10 | >10 |
Claims (36)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9611098P | 1998-08-10 | 1998-08-10 | |
US60/096,110 | 1998-08-10 | ||
US13135299P | 1999-04-28 | 1999-04-28 | |
US60/131,352 | 1999-04-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998095532A Division CN1257912C (zh) | 1998-08-10 | 1999-08-10 | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1478483A CN1478483A (zh) | 2004-03-03 |
CN100482236C true CN100482236C (zh) | 2009-04-29 |
Family
ID=26791121
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998095532A Expired - Lifetime CN1257912C (zh) | 1998-08-10 | 1999-08-10 | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 |
CNB2004100028639A Expired - Lifetime CN100387237C (zh) | 1998-08-10 | 1999-08-10 | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 |
CNB021265739A Expired - Lifetime CN100482236C (zh) | 1998-08-10 | 1999-08-10 | 用于治疗乙型肝炎的β-L-2’-脱氧-核苷 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998095532A Expired - Lifetime CN1257912C (zh) | 1998-08-10 | 1999-08-10 | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 |
CNB2004100028639A Expired - Lifetime CN100387237C (zh) | 1998-08-10 | 1999-08-10 | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 |
Country Status (22)
Country | Link |
---|---|
US (5) | US6395716B1 (zh) |
EP (2) | EP2415776B1 (zh) |
JP (2) | JP4294870B2 (zh) |
KR (4) | KR100634342B1 (zh) |
CN (3) | CN1257912C (zh) |
AT (1) | ATE313550T1 (zh) |
AU (1) | AU5475799A (zh) |
BR (1) | BRPI9912896B8 (zh) |
CA (1) | CA2340156C (zh) |
CY (2) | CY2007017I1 (zh) |
DE (2) | DE69929060T2 (zh) |
DK (3) | DK2415776T3 (zh) |
ES (3) | ES2531928T3 (zh) |
FR (1) | FR07C0046I2 (zh) |
HK (3) | HK1034083A1 (zh) |
LU (1) | LU91348I2 (zh) |
MX (1) | MXPA01001507A (zh) |
NL (1) | NL300286I2 (zh) |
PT (2) | PT2415776T (zh) |
RU (1) | RU2424016C2 (zh) |
SG (1) | SG132498A1 (zh) |
WO (1) | WO2000009531A2 (zh) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT831852E (pt) * | 1995-06-07 | 2007-02-28 | Uab Research Foundation | Nucleósidos com actividade anti-vírus da hepatite b |
WO2000009531A2 (en) * | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
EP1634888A3 (en) | 1999-11-12 | 2007-11-21 | Pharmasset, Inc. | Synthesis of 2'-deoxy-L-nucleosides |
TR200601783T2 (tr) * | 1999-11-12 | 2007-01-22 | Pharmasset Ltd | 2'-Deoksi-L-nükleositlerin sentezi |
BRPI0108435B8 (pt) * | 2000-02-29 | 2021-05-25 | Bristol Myers Squibb Co | formulação e uso de entecavir de baixa dose |
WO2001067772A2 (en) * | 2000-03-09 | 2001-09-13 | Videoshare, Inc. | Sharing a streaming video |
US6822089B1 (en) * | 2000-03-29 | 2004-11-23 | Isis Pharmaceuticals, Inc. | Preparation of deoxynucleosides |
BR0110023A (pt) | 2000-04-13 | 2003-12-30 | Pharmasset Ltd | Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
TR200402565T4 (tr) | 2000-05-26 | 2004-12-21 | Idenix (Cayman) Limited | Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı |
EP1294735A2 (en) | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Methods and compositions for treating flaviviruses and pestiviruses |
MY141594A (en) * | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
CN101250208B (zh) * | 2000-11-29 | 2012-06-20 | 三井化学株式会社 | L-核酸衍生物及其合成方法 |
JP3942414B2 (ja) | 2000-11-29 | 2007-07-11 | 三井化学株式会社 | L型核酸誘導体およびその合成法 |
WO2003053360A2 (en) | 2001-12-20 | 2003-07-03 | Pharmassett Ltd. | Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
JP2005514401A (ja) * | 2001-12-21 | 2005-05-19 | マイクロロジックス バイオテック,インコーポレイテッド | 抗ウイルス性7−デアザl−ヌクレオシド |
AU2003217863B9 (en) * | 2002-02-28 | 2009-10-29 | Biota Scientific Management Pty Ltd | Nucleotide mimics and their prodrugs |
DE60303131T2 (de) * | 2002-06-27 | 2006-07-20 | Medivir Ab | Synergistische wechselwirkung von abacavir und alovudin |
MXPA04012779A (es) | 2002-06-28 | 2005-08-19 | Idenix Cayman Ltd | Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae. |
KR20050035194A (ko) * | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘 |
CN101172993A (zh) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
RS114004A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited, | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
TWI244393B (en) * | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
AU2003278816A1 (en) * | 2002-09-13 | 2004-04-30 | Idenix (Cayman) Limited | ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES |
ATE442375T1 (de) | 2002-10-31 | 2009-09-15 | Metabasis Therapeutics Inc | Cytarabin-monophosphate prodrugs |
CN1849142A (zh) * | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
US7598373B2 (en) * | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
EP1745573A4 (en) | 2003-03-20 | 2010-05-26 | Microbiol Quimica Farmaceutica | PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES |
CN1812995A (zh) * | 2003-04-28 | 2006-08-02 | 艾登尼科斯(开曼)有限公司 | 工业化规模的核苷合成 |
WO2004096197A2 (en) * | 2003-05-02 | 2004-11-11 | Universita Degli Studi Di Cagliari | 5-aza-7-deazapurine nucleosides for treating flaviviridae |
EP2345661A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
WO2005003374A2 (en) | 2003-06-30 | 2005-01-13 | Idenix (Cayman) Limited | SYNTHESIS OF β-L-2-DEOXY NUCLEOSIDES |
CN1315863C (zh) * | 2003-12-12 | 2007-05-16 | 河南省科学院质量检验与分析测试研究中心 | β-L-2'-脱氧-核苷衍生物、其合成方法及其药物用途 |
AU2005285045B2 (en) | 2004-09-14 | 2011-10-13 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
EP1976382B1 (en) * | 2005-12-23 | 2013-04-24 | IDENIX Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
CN101466727B (zh) | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv抑制剂及其用途 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US20090082306A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telbivudine |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
SG172361A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside analogs |
AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
JP5779799B2 (ja) * | 2009-11-16 | 2015-09-16 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション, インコーポレーテッド | 2’−フルオロ−6’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法 |
EP2752422B1 (en) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
AU2011311880B2 (en) | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
CN102649788B (zh) * | 2011-02-28 | 2015-03-25 | 四川大学 | β-L-2’-脱氧-胸腺嘧啶核苷衍生物及其制备方法和用途 |
MD4589C1 (ro) | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
NZ625087A (en) | 2013-01-31 | 2017-05-26 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
CN110680806A (zh) * | 2018-07-04 | 2020-01-14 | 郑州泰丰制药有限公司 | 一种替比夫定颗粒的制备方法 |
CN108570078A (zh) * | 2018-07-18 | 2018-09-25 | 荆门医药工业技术研究院 | 一种制备1-O-乙酰基-2,3,5-三-O-苯甲酰基-β-D-呋喃核糖的方法 |
CN114133398B (zh) * | 2021-12-31 | 2022-11-22 | 中南民族大学 | 氨基酸取代的阿昔洛韦类三环核苷衍生物及其合成方法和应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB875971A (en) | 1959-01-14 | 1961-08-30 | Hoffmann La Roche | A process for the manufacture of uridine and thymidine derivatives and novel compounds concerned therein |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4916122A (en) | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
US5190926A (en) | 1987-01-28 | 1993-03-02 | University Of Georgia Research Foundation, Inc. | 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
AU2526188A (en) | 1987-09-22 | 1989-04-18 | Regents Of The University Of California, The | Liposomal nucleoside analogues for treating aids |
CA1329932C (en) | 1987-10-28 | 1994-05-31 | Reid Von Borstel | Acyl deoxyribonucleoside derivatives and uses thereof |
US6020322A (en) | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
JP2675864B2 (ja) | 1988-07-05 | 1997-11-12 | キヤノン株式会社 | 被記録材及びこれを用いたインクジェット記録方法 |
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
CA2083386C (en) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Phosphorous prodrugs |
WO1992001138A1 (en) | 1990-07-12 | 1992-01-23 | G-Drill Ab | Hydraulic down-the-hole rock drill |
EP0481214B1 (en) * | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
US5206244A (en) * | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
IT1246983B (it) | 1990-11-13 | 1994-12-12 | Consiglio Nazionale Ricerche | L-2'-desossiuridine e composizioni farmaceutiche che le contengono. |
IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
DE69233693T2 (de) | 1991-03-06 | 2008-01-24 | Emory University | Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B |
US5220003A (en) | 1991-03-29 | 1993-06-15 | The Regents Of The University Of California | Process for the synthesis of 2',3'-dideoxynucleosides |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
CA2112803A1 (en) | 1991-07-12 | 1993-01-21 | Karl Y. Hostetler | Antiviral liponucleosides: treatment of hepatitis b |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
AU6402594A (en) * | 1993-03-10 | 1994-09-26 | Wellcome Foundation Limited, The | Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides |
JP3693357B2 (ja) | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
WO1994026273A1 (en) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Acyclovir derivatives for topical use |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
CA2637774C (en) | 1993-09-10 | 2011-07-19 | Emory University | Nucleosides with anti-hepatitis b virus activity |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
WO1996011204A1 (de) * | 1994-10-07 | 1996-04-18 | Max-Delbrück-Centrum für Molekulare Medizin | NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG |
US5559101A (en) * | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
PT831852E (pt) * | 1995-06-07 | 2007-02-28 | Uab Research Foundation | Nucleósidos com actividade anti-vírus da hepatite b |
US6025335A (en) * | 1995-09-21 | 2000-02-15 | Lipitek International, Inc. | L-Nucleoside Dimer Compounds and therapeutic uses |
WO1999045935A1 (en) | 1998-03-11 | 1999-09-16 | Lipitek International, Inc. | Novel nucleoside analogs and uses in treating disease |
AU4716299A (en) | 1998-06-24 | 2000-01-10 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
WO2000009531A2 (en) * | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EP1294735A2 (en) * | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Methods and compositions for treating flaviviruses and pestiviruses |
TR200402565T4 (tr) * | 2000-05-26 | 2004-12-21 | Idenix (Cayman) Limited | Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı |
US6787526B1 (en) * | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
-
1999
- 1999-08-10 WO PCT/US1999/018149 patent/WO2000009531A2/en active IP Right Grant
- 1999-08-10 SG SG200302078-1A patent/SG132498A1/en unknown
- 1999-08-10 AT AT99941027T patent/ATE313550T1/de active
- 1999-08-10 CN CNB998095532A patent/CN1257912C/zh not_active Expired - Lifetime
- 1999-08-10 KR KR1020017001758A patent/KR100634342B1/ko active IP Right Grant
- 1999-08-10 DE DE69929060T patent/DE69929060T2/de not_active Expired - Lifetime
- 1999-08-10 BR BRPI9912896A patent/BRPI9912896B8/pt not_active IP Right Cessation
- 1999-08-10 DE DE200712000062 patent/DE122007000062I1/de active Pending
- 1999-08-10 CN CNB2004100028639A patent/CN100387237C/zh not_active Expired - Lifetime
- 1999-08-10 PT PT101846574T patent/PT2415776T/pt unknown
- 1999-08-10 RU RU2006147216/04A patent/RU2424016C2/ru active Protection Beyond IP Right Term
- 1999-08-10 DK DK10184657.4T patent/DK2415776T3/en active
- 1999-08-10 MX MXPA01001507A patent/MXPA01001507A/es active IP Right Grant
- 1999-08-10 JP JP2000564981A patent/JP4294870B2/ja not_active Expired - Lifetime
- 1999-08-10 KR KR1020067007301A patent/KR100691737B1/ko not_active IP Right Cessation
- 1999-08-10 CA CA002340156A patent/CA2340156C/en not_active Expired - Lifetime
- 1999-08-10 ES ES04075926.8T patent/ES2531928T3/es not_active Expired - Lifetime
- 1999-08-10 CN CNB021265739A patent/CN100482236C/zh not_active Expired - Lifetime
- 1999-08-10 ES ES99941027T patent/ES2255295T3/es not_active Expired - Lifetime
- 1999-08-10 DK DK99941027T patent/DK1104436T3/da active
- 1999-08-10 KR KR1020057009515A patent/KR100568035B1/ko not_active IP Right Cessation
- 1999-08-10 KR KR1020067007304A patent/KR100702230B1/ko not_active IP Right Cessation
- 1999-08-10 US US09/371,747 patent/US6395716B1/en not_active Expired - Lifetime
- 1999-08-10 ES ES10184657.4T patent/ES2579903T3/es not_active Expired - Lifetime
- 1999-08-10 DK DK04075926T patent/DK1431304T3/en active
- 1999-08-10 PT PT4075926T patent/PT1431304E/pt unknown
- 1999-08-10 AU AU54757/99A patent/AU5475799A/en not_active Abandoned
- 1999-08-10 EP EP10184657.4A patent/EP2415776B1/en not_active Expired - Lifetime
- 1999-08-10 EP EP99941027A patent/EP1104436B1/en not_active Expired - Lifetime
-
2001
- 2001-06-26 HK HK01104418A patent/HK1034083A1/xx not_active IP Right Cessation
- 2001-12-14 US US10/022,276 patent/US6569837B1/en not_active Expired - Lifetime
-
2003
- 2003-05-13 US US10/438,167 patent/US20030225028A1/en not_active Abandoned
-
2005
- 2005-09-22 US US11/232,818 patent/US7304043B2/en not_active Expired - Lifetime
-
2007
- 2007-05-07 JP JP2007122896A patent/JP2007269798A/ja active Pending
- 2007-05-21 HK HK07105364.0A patent/HK1097776A1/xx not_active IP Right Cessation
- 2007-07-18 LU LU91348C patent/LU91348I2/fr unknown
- 2007-08-06 CY CY200700017C patent/CY2007017I1/el unknown
- 2007-08-09 NL NL300286C patent/NL300286I2/nl unknown
- 2007-09-21 FR FR07C0046C patent/FR07C0046I2/fr active Active
- 2007-10-30 US US11/929,807 patent/US20080064655A1/en not_active Abandoned
-
2008
- 2008-06-24 HK HK08107009.6A patent/HK1111913A1/xx not_active IP Right Cessation
-
2015
- 2015-03-02 CY CY20151100218T patent/CY1116988T1/el unknown
Non-Patent Citations (3)
Title |
---|
《新药设计原理与方法》. 徐文方主编,123页,中国医药科技出版社. 1997 |
Design and synthesis of2',3'-dideoxy-2',3'-didehydro-β-L-cytidine(β-L-d4c) and2',3'-dideoxy-2',3'-didehydro-β-L-5-fluorocytidine(β-L-fd4c),Two exceptionally potent inhibitors of human hepatitis Bvirus(HBV) and potent inhibitors of human immunodeficien. Tai shun Lin et al.Journal Of Medicinal Chemistry,Vol.39 No.9. 1996 |
Design and synthesis of2',3'-dideoxy-2',3'-didehydro-β-L-cytidine(β-L-d4c) and2',3'-dideoxy-2',3'-didehydro-β-L-5-fluorocytidine(β-L-fd4c),Two exceptionally potent inhibitors of human hepatitis Bvirus(HBV) and potent inhibitors of human immunodeficien. Tai shun Lin et al.Journal Of Medicinal Chemistry,Vol.39 No.9. 1996 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100482236C (zh) | 用于治疗乙型肝炎的β-L-2’-脱氧-核苷 | |
US6566344B1 (en) | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | |
CA2410488C (en) | Methods of treating hepatitis delta virus infection with .beta.-l-2' deoxy-nucleosides | |
AU2013203196B2 (en) | Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B | |
CN1911237B (zh) | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 | |
AU2004201286B2 (en) | Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B | |
AU2007216721B2 (en) | Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B | |
EP1431304B1 (en) | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | |
CA2599597A1 (en) | .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: AIDAN KNICKS (CAYMAN) CO., LTD. Free format text: FORMER OWNER: IDENIX PHARMACEUTICAL CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040611 Address after: Cayman Islands Applicant after: Idenix Cayman Ltd. Co-applicant after: Centre National De La Recherche Scientifique Address before: Cayman Islands (Great Britain), Grand Cayman Applicant before: Aidan Nicks pharmaceuticals Co-applicant before: Centre National De La Recherche Scientifique |
|
ASS | Succession or assignment of patent right |
Owner name: FRANCE SCIENTIFIC RESEARCH NATIONAL CENTER MONTPE Free format text: FORMER OWNER: FRANCE SCIENTIFIC RESEARCH NATIONAL CENTER Effective date: 20040924 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040924 Address after: Cayman Islands Applicant after: Idenix Cayman Ltd. Co-applicant after: Centre National De La Recherche Scientifique Co-applicant after: Univ. Montpellier II Address before: Cayman Islands Applicant before: Idenix Cayman Ltd. Co-applicant before: Centre National De La Recherche Scientifique |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: IDENIX PHARMACEUTICALS, INC. Free format text: FORMER OWNER: IDENIX (CAYMAN) LIMITED Effective date: 20120710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120710 Address after: Massachusetts, USA Co-patentee after: Centre National De La Recherche Scientifique Patentee after: Aidan Nicks pharmaceuticals Ltd Co-patentee after: Univ. Montpellier II Address before: Cayman Islands Co-patentee before: Centre National De La Recherche Scientifique Patentee before: Idenix Pharmaceuticals Inc. Co-patentee before: Univ. Montpellier II |
|
ASS | Succession or assignment of patent right |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER OWNER: IDENIX PHARMACEUTICALS, INC. Effective date: 20130503 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130503 Address after: Basel Patentee after: Novartis Ag Patentee after: Centre National De La Recherche Scientifique Patentee after: Univ. Montpellier II Address before: Massachusetts, USA Patentee before: Aidan Nicks pharmaceuticals Ltd Patentee before: Centre National De La Recherche Scientifique Patentee before: Univ. Montpellier II |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090429 |